Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A registrational trial of AGEN-1181 in combination with Balstilimab

Next Previous
X
Search
Trial Profile

A registrational trial of AGEN-1181 in combination with Balstilimab

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Balstilimab (Primary) ; Botensilimab (Primary)
  • Indications Colorectal cancer; Solid tumours
  • Focus Registrational; Therapeutic Use
  • Sponsors Agenus

    • Most Recent Events

    • 18 Jul 2024 According to an Agenus media release, The FDA recommended the inclusion of a BOT monotherapy arm at Agenus' discretion in the Phase 3 study.
    • 05 May 2024 According to an Agenus media release, today announced that the companies have entered into a royalty financing agreement to support Agenus' key development initiatives in the ongoing BOT/BAL clinical development program, including its planned confirmatory Phase 3 trial in its lead indication of patients with metastatic, relapsed/refractory colorectal cancer.
    • 07 Nov 2023 According to an Agenus media release, company plans to submit an EU marketing authorization filing in 2025. Interactions with regulatory agencies are ongoing.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top